Guardant Health, Inc. (GH)

Market Cap	16.98B +236.6%
Revenue (ttm)	1.08B +39.6%
Net Income	-433.19M
EPS	-3.40
Shares Out	132.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,076,597
Open	127.00
Previous Close	129.69
Day's Range	124.81 - 130.44
52-Week Range	39.70 - 133.97
Beta	1.49
Analysts	Strong Buy
Price Target	131.24 (+2.5%)
Earnings Date	May 7, 2026

About GH

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 2,506
• Stock Exchange: NASDAQ
• Ticker Symbol: GH
• Website: https://guardanthealth.com

Financial Performance

In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.

Analyst Summary

According to 22 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $131.24, which is an increase of 2.50% from the latest price.

Price Target

$131.24

(2.50% upside)

Analyst Consensus: Strong Buy